You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞銀下調藥明生物(02269.HK)目標價至68元 對其2024至2025三成增長指引轉為更保守
阿思達克 06-21 09:46
瑞銀發表報告指,藥明生物(02269.HK)周二(20日)股價急挫17%,主要是投資者發現其今年上半年收入指引為低雙位數增長,而新項目數目為25個,均低於預期。公司對於「跟隨並贏得分子」戰略有信心,並重申今年收入指引為按年升30%。該行認為市場過度反應,並相信公司今年目標是可達到,主要是管理層過往有良好的往績紀錄,以及CDMO業務性質。但該行指,對公司2024至2025年增長錄得三成的指引,轉為更保守的看法。 該行表示,將公司今年至2025年各年收入預測分別下調0.1%、1.9%及3%,主要是考慮到本地資金持續疲軟,而公司每股盈測則各下調至1.29元人民幣、1.64元人民幣及2.14元人民幣,同時亦將其目標價由74元下調至68元,維持其評級為「買入」。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account